Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproNPRRF 74 Cash-to-Debt is 0.16 as of Jun. 2026, which is 6% below its 10-year median of 0.17. GuruFocus rates NPRRF with a GF Score™ of 74/100 and a GF Value™ of $10.26. The stock has 6 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Nipro ranks worse than 86.94% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nipro's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.16.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Niprocouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Nipro's Cash-to-Debt or its related term are showing as below:
NPRRF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 0.17 Max: 0.27
Current: 0.16
During the past 13 years, Nipro's highest Cash to Debt Ratio was 0.27. The lowest was 0.15. And the median was 0.17.
NPRRF's Cash-to-Debt is ranked worse than 86.94% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs NPRRF: 0.16
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Nipro Cash-to-Debt Related Terms
Nipro Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Nipro's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Nipro's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Nipro's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (NPRRF) has a Cash-to-Debt of 0.16 as of Jun. 2026. This is near median its historical median of 0.17. Over the past decade, Nipro's Cash-to-Debt has ranged from 0.15 to 0.27. According to the industry distribution chart, Nipro ranks #732 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 86.9%.
Is Nipro's Cash-to-Debt too high?
Nipro's current Cash-to-Debt of 0.16 is near median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.27. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Nipro's value of 0.16 is 90.2% below this industry median. Based on the distribution chart, Nipro ranks #732 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nipro has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Nipro's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #732 out of 842 companies for Cash-to-Debt. This places Nipro in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Nipro's value of 0.16 is 90.2% below this benchmark. Historically, Nipro's own Cash-to-Debt has ranged from 0.15 to 0.27 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 1.64, Nipro has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nipro's current Cash-to-Debt of 0.16 is 90.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nipro's current Cash-to-Debt is 0.16, which is near median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Nipro (NPRRF) has a current Cash-to-Debt of 0.16. The stock's GF Value™ is $10.26, compared to a current price of $9.96 — trading 2.9% below its estimated fair value. The current Cash-to-Debt is 0.16, which is near median its 10-year median of 0.17 and 90.2% below the Medical Devices & Instruments industry median of 1.64. Nipro's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Nipro (NPRRF), the current Cash-to-Debt is 0.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (NPRRF) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be undervalued.
The current stock price of $9.96 is trading 2.9% below its estimated GF Value™ of $10.26.
Key valuation signals for NPRRF:
Cash-to-Debt: 0.16 (near median its 10-year median of 0.17)
GF Value™: $10.26 vs. price of $9.96 (2.9% below fair value)
Industry Position: 90.2% below the Medical Devices & Instruments median (#732 of 842)
No single metric tells the full story. See the NPRRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
74GF Score
Get the complete analysis for NPRRF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPRRF has been successfully added to your 
